Masimo (NASDAQ:MASI) PT Raised to $207.00

Share on StockTwits

Masimo (NASDAQ:MASI) had its target price raised by UBS Group from $190.00 to $207.00 in a report released on Thursday, BenzingaRatingsTable reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other equities analysts have also recently weighed in on the company. BidaskClub raised Masimo from a buy rating to a strong-buy rating in a report on Wednesday, January 22nd. Piper Sandler reissued a buy rating and issued a $175.00 price target on shares of Masimo in a report on Wednesday, January 15th. Finally, Piper Jaffray Companies reissued an overweight rating and issued a $175.00 price target (up from $161.00) on shares of Masimo in a report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $177.36.

NASDAQ MASI opened at $178.37 on Thursday. Masimo has a fifty-two week low of $118.93 and a fifty-two week high of $186.91. The stock has a market cap of $9.51 billion, a price-to-earnings ratio of 51.85, a price-to-earnings-growth ratio of 2.18 and a beta of 1.11. The business has a fifty day moving average of $171.39 and a 200-day moving average of $156.20.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, February 19th. The medical equipment provider reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.04. Masimo had a return on equity of 17.03% and a net margin of 20.92%. The company had revenue of $247.51 million during the quarter, compared to analysts’ expectations of $243.79 million. During the same period in the previous year, the firm posted $0.83 earnings per share. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, analysts forecast that Masimo will post 3.56 EPS for the current fiscal year.

In other news, EVP Thomas Samuel Mcclenahan sold 500 shares of Masimo stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total value of $79,645.00. Following the completion of the sale, the executive vice president now owns 5,607 shares of the company’s stock, valued at $893,139.03. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $175.00, for a total value of $1,750,000.00. Following the completion of the sale, the director now directly owns 76,245 shares of the company’s stock, valued at approximately $13,342,875. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,378 shares of company stock valued at $9,435,640. Company insiders own 11.50% of the company’s stock.

Several large investors have recently made changes to their positions in MASI. Great Diamond Partners LLC purchased a new stake in Masimo during the fourth quarter valued at about $29,000. Flagship Harbor Advisors LLC grew its position in Masimo by 45.7% during the third quarter. Flagship Harbor Advisors LLC now owns 236 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 74 shares during the period. West Oak Capital LLC grew its position in Masimo by 62.5% during the fourth quarter. West Oak Capital LLC now owns 325 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 125 shares during the period. Procyon Private Wealth Partners LLC purchased a new stake in Masimo during the fourth quarter valued at about $54,000. Finally, Exchange Traded Concepts LLC purchased a new stake in Masimo during the fourth quarter valued at about $71,000. 84.20% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Read More: Dividend Achievers

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.